Siga Seeks to Re-Argue Ruling in PharmAthene Smallpox Case

Siga Technologies Inc. asked a Delaware judge to reconsider his award of 50 percent of the profit from a smallpox drug to rival PharmAthene Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.